Comparison of Anti Hypertensive Effect of Fixed Dose Enalapril and Losartan in Essential Hypertension by Mansoor, Khurram
Journal of Rawalpindi Medical College (JRMC); 2009;13(1):26-29 
 26 
Comparison of Anti Hypertensive Effect of Fixed Dose 
Enalapril and Losartan in Essential Hypertension 
 
 
Khurram Mansoor, Syed Hamid Ali Shah, Liaqat Ali, 
 
Department of Medicine, Military Hospital Rawalpindi 
 
 
Abstract 
 
Background: Angiotensin converting enzyme inhibitors 
and angiotensin receptor blockers are being extensively 
used these days for treatment of mild to moderate 
hypertension. The selection of either of the two drugs is 
usually based on physician preference. The purpose of the 
study was to  compare antihypertensive effect of fixed 
dose Enalapril and Losartan in Essential Hypertension. 
Methods: In this interventional study therapeutic option 
of Enalapril (Group 1) ) and  Losartan (Group 2) were 
offered to 100 newly diagnosed cases of hypertension . 
The patients were  followed on subsequent visits (6 in 
total) and the systolic and diastolic blood pressures were 
recorded carefully. 
Results: Total number of patients becoming 
normotensive with Enalapril was 38  (out of 50) and with 
Losartan were 28 (out of 50).  
Conclusion: Enalapril had significantly better 
antihypertensive effect than Losartan in essential 
hypertension at the end of six months therapy. 
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Introduction 
 
Hypertension is an increasingly important 
medical and public health issue. The prevalence of 
hypertension increases with advancing age to the point 
where more than half of people aged 60 to 69 years 
and approximately three-fourths of those aged 70 
years and older are affected. 
Framingham Heart Study investigators 
recently reported the lifetime risk of hypertension to 
be approximately 90% for men and women who were 
nonhypertensive at 55 or 65 years and survived to age 
80 to 85.1 
Diastolic blood pressure is a more potent 
cardiovascular risk factor than systolic blood pressure 
until age 50; thereafter, systolic blood pressure is more 
important .2 
  Clinical trials have demonstrated that control 
of isolated systolic hypertension reduces total 
mortality, cardiovascular mortality and stroke.3 Both 
observational studies and clinical trial data suggest 
that poor systolic blood pressure control is largely 
responsible for the unacceptably low rates of overall 
blood pressure control.4,5  In the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT) and Controlled Onset Verapamil 
Investigation of Cardiovascular End Points 
(CONVINCE) trial, diastolic blood pressure control 
rates exceeded 90%, but systolic blood pressure control 
rates were considerably less (60 to 70%).6,7  Poor 
systolic blood pressure control is at least in part 
related to physician attitudes. A survey of primary 
care physicians indicated that three-fourths of them 
failed to initiate antihypertensive therapy in older 
individuals with SBP of 140 to 159 mm Hg, and most 
primary care physicians did not pursue control to less 
than 140 mm Hg.8 It has also been shown that pulse 
pressure is an independent marker of cardiovascular 
risk, mainly for myocardial infarction.9  
  Increased pulse pressure is also a predictor of 
cardiovascular risk in subjects with recurrent 
myocardial infarction and congestive heart failure.10  
ACE inhibitors have achieved widespread 
usage in the treatment of cardiovascular and renal 
disease. ACE inhibitors alter the balance between the 
vasoconstrictive, salt-retentive, and hypertrophic 
properties of angiotensin II and the vasodilatory and 
natriuretic properties of bradykinin. They  alter the 
metabolism of a number of other vasoactive 
substances as well. They have proved effective in the 
treatment of hypertension, they decrease mortality in 
congestive heart failure and left ventricular 
dysfunction after myocardial infarction, and they delay 
the progression of diabetic nephropathy.  The purpose 
of this  study was to compare the anti hypertensive 
effect of  fixed dose Enalapril and Losartan in essential 
hypertension . 
 
Patients and Methods 
   
 This interventional study was conducted in 
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the department of Medicine Military Hospital 
Rawalpindi. 100 patients of essential hypertension 
coming to the OPD of the hospital were selected and 
divided into 2 groups with 50 patients in each group 
by using table of random numbers.  
Keeping in view the possibility of poor drug 
compliance and those patients who might fail to 
appear for regular follow up visits, 15 additional   
patients were included in both study groups. At the 
end of the study period only those 50 patients were 
considered in each group who were strictly compliant 
with drugs and reported regularly for all follow up 
visits.  
Inclusion Criteria 
The patients who provided informed written consent. 
Both males and females, between 25 – 70 years of age  
Patients of essential hypertension ( Systolic blood 
pressure > 140 mm Hg and Diastolic blood pressure > 
90 mmHg ) with poor control of hypertension on diet 
alone, reporting in medical OPD Military Hospital 
Rawalpindi. 
Exclusion Criteria 
Patients with Secondary hypertension. 
Patients who had any critical illness with expected life 
expectancy less than 6 months. 
A female who was lactating, pregnant or was planning 
to become pregnant during the course of study.  
Patients with co-morbid conditions like unstable 
angina, congestive cardiac failure and renal 
impairment. 
Patients who had already experienced side effects of 
these two drugs. 
Patients with history of alcohol or drug abuse. 
Study Group 1 was given Tablet Enalapril 10 mg 
and Study Group 2 received Tablet Losartan 50 mg. 
 
Results 
 
The mean age of group 1 was 51, and that of group 
2 was 50.58 while total mean age of 100 patients was 50.79 
years with a standard deviation ±12.13 years (Table 1). 
Gender distribution of total 100 patients included 62 % 
males and 38% females. Individual groups had gender 
distribution such that there were 64 % males and 36 % 
females in group 1. In other words there were 32 males and 
18 females in this group. Whereas in the other study group 
(group 2) there were 60 % males and 40 % females. This 
included 30 males and 20 females.  
In group 1 the initial mean systolic blood pressure 
value of the entire group was found to be 178.92 mm Hg, 
with maximum value being 194 mm Hg and minimum value 
being 166 mm Hg. On second visit the mean systolic blood 
pressure value of the same study group became 144.60mm 
Hg, the latter values on subsequent visits (third visit to sixth 
visit) were 140.64, 134.22, 131.04 and 125.50 mm Hg 
respectively. In the same study group (group 1) the mean 
diastolic blood pressure at the time of initial presentation 
(visit 1) and on later follow up visits (second to sixth visits) 
were 109.10,101.74, 94.24, 87.32, 81.74 and 76.50 mm Hg 
respectively. (Figs 1 and 2)  
 
Table 1: Mean Age of the Patients 
 n = 100 
Study Group Mean Standard deviation 
Study Group 1 
(ENALAPRIL) 51 11.8 
Study Group 2 
(LOSARTAN) 50.58 12.50 
Total 50.79 12.13 
 
0
100
200
Group 1 179 145 141 134 131 126
Group 2 179 155 150 155 141 139
1 2 3 4 5 6
Figure1: Mean Systolic Blood Pressures of 
Study Group 1 (Enlapril) And 2 (Losartan) 
On Visits 1 To 6 
 
In the study group 2 the mean systolic blood 
pressure value was found to be 178.64 mm Hg on first visit. 
Maximum value was found to be 192 mm Hg and minimum 
value being 168 mm Hg. On first subsequent visit the mean 
systolic blood pressure value became 154.78 mm Hg. On 
later follow up visits these values were found to be 149.58, 
145.22, 141.30 and 138.58 mm Hg. In this study group the 
mean diastolic blood pressure at the time of presentation 
was 109.16 mm Hg and on later follow up visits were 
105.60, 101.56, 98.70, 94.02 and 90.64 mm Hg respectively 
(Figs 1 and 2). 
It was found that 66 out of 100 patients in both 
the study groups became normotensive. They were 38 
in group 1 and 28 in group 2. 
The mean systolic and diastolic blood 
pressures of each study group were compared within 
the same group by using paired sample t test (p <0.05). 
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 As a final comparison of the mean systolic 
and diastolic blood pressures thus obtained, from both 
the drugs (Enalapril and Losartan) were compared 
with each other by using independent sample t test (p 
value of < 0.05).  
 
 
Figure 2: Mean Diastolic Blood Pressures of 
Study Group 1 (Enalapril) and 2 (Losartan) 
on Visits 1 To 6 
 
Discussion 
 
The evidence based utilization of the 
antihyperteinsive drugs is still  lacking in our set up, 
thus selection of either of these agents for treatment is 
more of physician’s choice   
  This  study reflected that out of 130 patients 
who were included in the study initially only 113 
patients were strictly compliant with drugs and 
appeared regularly for all follow up visits. It included 
53 patients from Study group 1 and 60 patients in 
Study group 2. Out of these patients we further 
considered 50 patients for each Study group without 
following any special criteria for accepting one patient 
and rejecting the other  
 In international study trials we could 
appreciate that their results were different from our 
own study results. In a relatively smaller trial ( n = 30 ) 
by Chowta et al  (2002) losartan  was demonstrated to 
have similar anti hypertensive effect as that of 
enalapril.11  It was an open, enalapril controlled study 
which was conducted in 30 patients with mild to 
moderate hypertension. Losartan 50 mg was 
administered to patients for eight weeks. Throughout 
the study blood pressure was measured every two 
weeks. After eight weeks losartan was stopped and 
enalapril 10 mg daily was administered to the same 
patients after two weeks washout period. The same 
methodology that was followed for losartan trial was 
repeated for enalapril trial also. Losartan treatment 
resulted in a highly significant reduction in the mean 
sitting diastolic blood pressure. The percentage of 
responders was slightly more with losartan than 
enalapril (86.7% vs 76.7%). 
Another study was conducted in 
Hypertension Unit, Department of Internal Medicine, 
Hospital Clinic, Barcelona, Spain.  The aim of this 
study was to compare the antihypertensive efficacy of 
the combination enalapril 10 mg/nitrendipine 20 mg 
vs. losartan 50 mg/hydrochlorothiazide 12.5 mg , 
assessed by 24-h ambulatory blood pressure 
monitoring. This multi centre, double-blind, parallel 
study included 97 hypertensive patients (diastolic 
blood pressure 90-109 mmHg and daytime > 85 
mmHg). After a 2- to 3-week period of single-blind 
placebo, they were randomized to receive double-
blind treatment with Enalapril (n = 48) or Losartan (n 
= 49) for a 4-week period. 
 The primary outcome measure was the 
difference in 24 hours diastolic blood pressure 
reduction between treatments from randomization to 
the end of the double-blind period.  
No significant differences were observed in 
the primary outcome measure only the difference in 
the rate of systolic blood pressure control (< 140 
mmHg) reached statistical significance (42.2 vs 22.4%; 
p = 0.048).  It was thus concluded that enalapril and 
losartan have a similar antihypertensive efficacy, 
assessed by ambulatory blood pressure monitoring. 
Enalapril achieved a significantly higher systolic blood 
pressure control rate, but this was accompanied by an 
apparently higher proportion of mild adverse events.12  
 
Conclusion 
 
Enalapril has significantly better 
antihypertensive effect than Losartan in patients of 
mild to moderate hypertension. More studies need to 
be conducted on the same topic in our local set up in 
order to have clear guidelines for our own 
consumption. 
 
References 
 
1. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, 
D’Agostino RB, et al. Residual lifetime risk for developing 
hypertension in middle-aged women and men: The 
Framingham Heart Study. JAMA, 2002; 287: 1003–10 
2. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, 
Kannel W B, et al. Does the relation of blood pressure to 
coronary heart disease risk change with aging? The 
Framingham Heart Study. Circulation, 2001; 103: 1245–
49. 
3. Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de 
Leeuw PW, et al. Predicting cardiovascular risk using 
conventional vs ambulatory blood pressure in older 
patients with systolic hypertension. Systolic Hypertension 
in Europe Trial Investigators. JAMA, 1999; 282: 539–46. 
Journal of Rawalpindi Medical College (JRMC); 2009;13(1):26-29 
 29 
4. Hyman DJ, Pavlik VN. Characteristics of patients with 
uncontrolled hypertension in the United States. N Engl J 
Med, 2001; 345: 479–86. 
5. Lloyd-Jones DM, Evans JC, Larson MG, O’Donnell CJ, 
Roccella EJ, Levy D. Differential control of systolic and 
diastolic blood pressure: factors associated with lack of 
blood pressure control in the community. Hypertension, 
2000; 36: 594–99. 
6. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, 
Grimm RH, et al. Success and predictors of blood pressure 
control in diverse North American  
settings: The Antihypertensive and Lipid- 
7. Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT). J Clin Hypertens (Greenwich), 2002; 4: 393–04. 
8. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, 
Grimm R, et al. Baseline characteristics and early blood 
pressure control in the CONVINCE trial. Hypertension, 
2001; 37: 12–18. 
9. Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of 
awareness and control of hypertension. J Clin Hypertens 
(Greenwich), 2000; 2: 324–30. 
10. Hajjar I, Kotchen TA. Trends in prevalence, awareness, 
treatment, and control of hypertension in the United States, 
1988–2000. JAMA, 2003; 290: 199–2006. 
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green 
LA, Izzo JL Jr, et al.   The seventh report of the Joint 
National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure: the JNC 7 Report. 
JAMA, 2003; 289: 2560–72. 
12. Chowta KN, Chowta MN, Bhat P, Adhikari PM.. An open 
comparative clinical trial to assess the efficacy and safety of 
losartan versus enalapril in mild to moderate hypertension. 
J Assoc Physicians India, 2002;50:1236-39 
13.  de la Sierra A, Gil-Extremera B, Calvo C, Campo C, 
Garcia-Puig J, Marquez E, et al .Comparison of the 
antihypertensive effects of the fixed dose combination 
enalapril 10 mg/nitrendipine 20 mg vs losartan 50 
mg/hydrochlorothiazide 12.5 mg, assessed by 24-h 
ambulatory blood pressure monitoring, in essential 
hypertensive patients. J Hum Hypertens, 2004;18(3):215-
22. 
 
